Cargando…

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer

Androgen receptor (AR) is widely expressed in different subtypes of breast cancer (BC). However, it is unclear how AR functions in HER2 positive (+) BC. Knockdown of AR with shRNAs and a new generation anti-androgen drug, Enzalutamide, were used to explore the involvement of AR on the growth of HER2...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Licai, Du, Zhuanyun, Xiong, Xusheng, Ma, Hua, Zhu, Zhenfeng, Gao, Hongwei, Cao, Jiawei, Li, Tong, Li, Hongzhi, Yang, Kaiyan, Chen, Guorong, Richer, Jennifer K., Gu, Haihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674043/ https://www.ncbi.nlm.nih.gov/pubmed/29109513 http://dx.doi.org/10.1038/s41598-017-14607-2

Ejemplares similares

The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice
por: Li, Panyuan, et al.
Publicado: (2020)

USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α
por: Cao, Jiawei, et al.
Publicado: (2021)

Mammary tumor growth and metastasis are reduced in c‐Kit mutant Sash mice
por: He, Licai, et al.
Publicado: (2016)

Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model
por: Wu, Guang, et al.
Publicado: (2022)

24‐Dehydrocholesterol reductase promotes the growth of breast cancer stem‐like cells through the Hedgehog pathway
por: Qiu, Ting, et al.
Publicado: (2020)

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy
por: Li, Jiayi, et al.
Publicado: (2022)

Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis
por: Yu, Yushuai, et al.
Publicado: (2023)

Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol
por: Murray, Nigel P., et al.
Publicado: (2011)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
por: Cao, Guo-dong, et al.
Publicado: (2017)

How we treat HER2-positive brain metastases
por: Stavrou, E., et al.
Publicado: (2021)

MRI-Based Radiomic Signature as a Prognostic Biomarker for HER2-Positive Invasive Breast Cancer Treated with NAC
por: Li, Qin, et al.
Publicado: (2020)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2021)

Correction: Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2023)

Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes
por: Orrù, Sandra, et al.
Publicado: (2022)

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
por: Liu, Zimin, et al.
Publicado: (2021)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Advances in treating HER2-positive breast cancer: an interview with Sunil Verma
por: Verma, Sunil
Publicado: (2014)

How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)

A new paradigm for classifying and treating HER2‐positive breast cancer
por: He, Xuexin, et al.
Publicado: (2023)

Identification of low-overpressure interval and its implication to hydrocarbon migration: Case study in the Yanan sag of the Qiongdongnan Basin, South China Sea
por: Xu, Qinghai, et al.
Publicado: (2017)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

OR30-5 Androgen-Regulated Secreted Factors Promote Tumorigenesis and Immune Suppression in Breast Cancer
por: Richer, Jennifer, et al.
Publicado: (2022)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020)

Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma
por: Kawakita, Daisuke, et al.
Publicado: (2022)

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy
por: Lee, Eun-Gyeong, et al.
Publicado: (2023)

Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study
por: Zhao, Wei, et al.
Publicado: (2020)

Galectin‐3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2‐positive breast cancer cells
por: Chen, Yuqiu, et al.
Publicado: (2022)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
por: Guiu, S., et al.
Publicado: (2013)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
por: Li, Shuai, et al.
Publicado: (2020)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
por: Li, Xin, et al.
Publicado: (2021)

Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
por: Lu, Yujie, et al.
Publicado: (2023)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients
por: Cavalieri, Stefano, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q33almaqbi87dsggtg7pra0up8